Tiotropium

Generic Name: Tiotropium

Brand Names: Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₂NO_₄S_₂

CAS Number: 186691-13-4

Unique Ingredient Identifier: 0EB439235F

Background: Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.

Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.

Tiotropium was granted FDA approval on 30 January 2004.

Indication: Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.

Associated Conditions: Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD

Associated Therapies: -

Clinical Trials

Tiotropium for Smoking Asthmatics Study

Phase 4

Withdrawn

Conditions: Asthma

Interventions: Drug: long acting beta agonist
Drug: tiotropium

First Posted Date: 2007-10-18

Last Posted Date: 2016-05-26

Lead Sponsor: University of Alberta

Registration Number: NCT00546234

Locations: 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Royal University Hospital, Saskatoon, Saskatchewan, Canada

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Salmeterol
Drug: Ciclesonide low
Drug: Ciclesonide high
Drug: Fluticasone
Drug: Placebo

First Posted Date: 2007-09-26

Last Posted Date: 2014-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT00535366

Locations: 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪
1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱
1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands

and more 9 locations

Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QAT370
Drug: Placebo
Drug: Tiotropium

First Posted Date: 2007-09-20

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT00532350

Locations: 🇩🇪
Novartis investigative site, Berlin, Germany
🇩🇪
Novartis Investigative site, Wiesbaden, Germany

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium

First Posted Date: 2007-09-03

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 457

Registration Number: NCT00523991

Locations: 🇵🇹
205.365.1025 Boehringer Ingelheim Investigational Site, Amadora, Portugal
🇨🇿
205.365.1107 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czech Republic
🇨🇿
205.365.1079 Boehringer Ingelheim Investigational Site, Neratovice, Czech Republic

and more 59 locations